Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: An oxygen generator includes an adsorption tower and an exhaust muffler. The adsorption tower includes a loading cavity for loading a molecular sieve, and a nitrogen exhaust port in communication with the filling cavity; the exhaust muffler includes a gas inlet and a gas outlet, the gas inlet being in communication with the nitrogen exhaust port; and the exhaust muffler is configured to only allow a gas to flow unidirectionally from the gas inlet to the gas outlet. In the oxygen generator, the exhaust muffler is arranged at the nitrogen exhaust port of the adsorption tower, and the exhaust muffler is configured to only allow a gas to flow unidirectionally from the gas inlet to the gas outlet.

Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.

Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.

Abstract: The present invention relates to a multifunctional cyclic-dinucleotide compound of formula (X) and its derivatives, which can be used as a prodrug of an apoptosis inducer or a cytotoxic agent for inducing cell apoptosis or anti-virus, and can also regulate immunity pathway to generate a therapeutically beneficial immune response. The present disclosure further relates to pharmaceutical compositions and pharmaceutical combinations comprising the cyclic-dinucleotide compounds of the present invention, methods for synthesizing them, and medical uses thereof.

Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: Compounds which have the structure represented by formula (I) and can be used as KRas inhibitors, pharmaceutical compositions comprising this type of compounds, a method of preparing this type of compounds, and uses of these compounds in the treatment of cancers.

Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.

Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.

Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.

Abstract: The present invention relates to solid oral fixed dose compositions of metformin, atorvastatin, and valsartan, or their pharmaceutically acceptable salts, processes for the preparation thereof, and the use of the composition to treat certain diseases.

Abstract: Provided are a process and a device for preparing environmentally-friendly insulating gas perfluoroalkylnitrile. The device comprises a first tank reactor, a second tank reactor, and a fixed bed reactor. A condensing and collecting device is provided at the top of the first tank reactor, a collecting and guiding channel at the bottom of the condensing and collecting device is connected to an inlet of a storage tank, and an outlet of the storage tank is connected to an inlet of the second tank reactor. The second tank reactor is connected to a perfluoroolefin tank. An outlet of the second tank reactor is connected to a storage gasification tank. The storage gasification tank is connected to a carrier gas tank, and an outlet of the storage gasification tank is connected to an inlet of the fixed bed reactor. The present invention starts from cyanuric chloride and perfluoropropylene, and uses two tank reactors and a fixed bed reactor to realize production with high atom economy.

Abstract: Provided are a process and a device for preparing environmentally-friendly insulating gas perfluoroalkylnitrile. The device comprises a first tank reactor, a second tank reactor, and a fixed bed reactor. A condensing and collecting device is provided at the top of the first tank reactor, a collecting and guiding channel at the bottom of the condensing and collecting device is connected to an inlet of a storage tank, and an outlet of the storage tank is connected to an inlet of the second tank reactor. The second tank reactor is connected to a perfluoroolefin tank. An outlet of the second tank reactor is connected to a storage gasification tank. The storage gasification tank is connected to a carrier gas tank, and an outlet of the storage gasification tank is connected to an inlet of the fixed bed reactor. The present invention starts from cyanuric chloride and perfluoropropylene, and uses two tank reactors and a fixed bed reactor to realize production with high atom economy.

Abstract: The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of —CH2CH3 and phenyl; or R1 and R2 combine to form morpholino; and processes to prepare arzoxifene.

Abstract: The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of —CH2CH3 and phenyl; or R1 and R2 combine to form morpholino; and processes to prepare arzoxifene.

Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.

Abstract: The present invention relates to a one-pot process for preparing a compound of formula I: I; by reacting a compound of formula II with a compound of formula III: in the presence of a suitable solvent, a suitable base, a palladium catalyst and a suitable ligand.